ЛАГ: за рамками идиопатической формы патологии
https://doi.org/10.26442/2075082X.2020.2.200235
Аннотация
VIII Евразийский конгресс кардиологов. Обзор симпозиумов. ЛАГ: за рамками идиопатической формы патологии. Системные гипертензии.
Об авторах
Т. В. Мартынюк
Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России
Россия
Россия
А. А. Шмальц
ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России
Россия
Россия
А. А. Клименко
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия
Россия
Список литературы
1. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary artery hypertension: A randomized placebo-controlled study. Lancet 2001; 358: 1119-23
2. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903
3. Barst RJ, Ivy D, van Giersbergen PL et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Therapeutics 2003; 73: 372-82
4. Galiè N, Beghetti M, Gatzoulis MA et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54
5. Galie N, Rubin LJ, Jansa P et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized, controlled trial. Lancet 2008; 371: 2093-100
6. Sitbon O, Gressin V, Speich R et al. Bosentan in pulmonary arterial hypertension associated with HIV infection. Am J Respir Crit Care Med 2004; 170: 1212-7
7. Hughes RJ, Jais X, Bonderman D et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 year. Eur Respir J 2006; 28: 138-43
8. Bonderman D, Nowotny R, Skoro-Sajer N et al. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest 2005; 128: 2599-603
9. Provencher S, Sitbon O, Humbert M et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-95
10. Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92: 926-32
11. Rosenzweig EB, Ivy DD, Widlitz A et al. Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. JACC 2005; 46 (4): 697-704
12. Jais X, Ghofrani A, Hoeper MM et al. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a randomized, placebo-controlled trial. Am J Resp Crit Care Med 2007; 173: A896
13. Guillevin L, Gabrielli A, Peter H et al. Long-term effects of bosentan on quality of life (QoL), survival, safety and tolerability in pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD). Ann Rheum Dis 2006; 65 (Suppl. 2): 392
14. Keogh AM, McNeil KD, Wlodarczyk J et al. Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan. J Heart Lung Transplantation 2007; 26: 181-7
15. Galie N, Seeger W, Naeije R et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S-88S
16. Архипова О.А., Грацианская С.Е., Мартынюк Т.В. Оценка эффективности и безопасности первого российского генерического бозентана у пациентов с легочной артериальной гипертензией. Системные гипертензии. 2018; 15 (4): 53-8
17. McLaughlin V, Channick RN, Ghofrani H-A et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405-13
18. Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-4
19. Simonneau G, Montani D, Celermajer DS et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (1). DOI: 10.1183/13993003.01913-2018
20. Galie N, Beghettie M, Gatzoulis MA et al. Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. Circulation 2006; 114: 48-54
21. Galié N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67-119. DOI: 10.1093/eurheartj/ehv317
22. Hansmann G, Koestenberger M, Alastalo TP et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 2019; 38 (9): 879-901. DOI: 10.1016/j.healun.2019.06.022
23. Galie N et al. Treatment of Patients With Mildly Symptomatic Pulmonary Arterial Hypertension With Bosentan (EARLY Study): A Double-Blind, Randomised Controlled Trial. Lancet 2008; 371: 2093-100
24. McLaughlin V et al. Bosentan Added to Sildenafil Therapy in Patients With Pulmonary Arterial Hypertension. Eur Respir J 2015; 46: 405-13
25. Torbicki A et al, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005; 353 (20): 2148-57. DOI: 10.1056/NEJMoa050010
26. Simonneau G et al. Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients With Pulmonary Arterial Hypertension: A Randomized Trial. Ann Intern Med 2008; 149: 521-30
27. Pulido T et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809-18
28. Ghofrani HA, Galiè N, Grimminger F et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369 (4): 330-40. DOI: 10.1056/NEJMoa1209655
29. Beghetti M, Channick RN, Chin KM et al. Selexipag Treatment for Pulmonary Arterial Hypertension Associated With Congenital Heart Disease After Defect Correction: Insights From the Randomised Controlled GRIPHON Study. Eur J Heart Fail 2019; 21 (3): 352-9. DOI: 10.1002/ejhf.1375
30. Rosenkranz S, Ghofrani HA, Beghetti M et al. Riociguat for Pulmonary Arterial Hypertension Associated With Congenital Heart Disease. Heart 2015; 101 (22): 1792-9. DOI: 10.1136/heartjnl-2015-307832
31. Beghetti M, Channick RN, Chin KM et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail 2018. DOI: 10.1002/ejhf.1375
32. Galie N et al. Evaluation of macitentan in patients with Eisenmenger syndrome: Results from the randomised controlled MAESTRO study. Eur Heart J 2017; 38 (Suppl 1): P5462. https://academic.oup.com/eurheartj/article/38/suppl_1/ehx493.P5462/4086822
33. Singh TP, Rohit M, Grover A et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151 (4): 851.e1-5. DOI: 10.1016/j.ahj.2005.09.006
34. Sun YJ, Yang T, Zeng WJ et al. Impact of sildenafil on survival of patients with Eisenmenger syndrome. J Clin Pharmacol 2013; 53 (6): 611-8
35. Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger’s syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. Cardiol Young 2011; 21 (6): 631-8. DOI: 10.1017/s1047951111000497
36. Zhang Z-N, Jiang X, Zhang R et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 2011; 97 (22): 1876-81. DOI: 10.1136/heartjnl-2011-300344
37. Zuckerman WA, Leaderer D, Rowan CA et al. Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease. Am J Cardiol 2011; 107 (9): 1381-5. DOI: 10.1016/j.amjcard.2010.12.051
38. Min Ku Chon, Kyoung Im Cho, Kwang Soo Cha et al. Effects of Long-Term Iloprost Treatment on Right Ventricular Function in Patients With Eisenmenger Syndrome. J Cardiol 2017; 69 (5): 741-6. DOI: 10.1016/j.jjcc.2016.07.002
39. Dimopoulos K, Inuzuka R, Goletto S et al. Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy for Pulmonary Arterial Hypertension. Circulation 2010; 121 (1): 20-5. DOI: 10.1161/CIRCULATIONAHA.109.883876
40. Li Q, Kuang HY, Wu YH et al. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis. Medicine 2019; 98 (20): e15632. DOI: 10.1097/md.0000000000015632
41. Kuang HY, Wu YH, Yi QJ et al. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97 (10): e0075. DOI: 10.1097/MD.0000000000010075
42. Varela DL, Teleb M, El-Mallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review. Open Heart 2018; 5 (1): e000744. DOI: 10.1136/openhrt-2017-000744
43. Kozlik-Feldman R et al. Pulmonary Hypertension in Children With Congenital Heart Disease (PAH-CHD, PPHVD-CHD). Expert Consensus Statement on the Diagnosis and Treatment of Paediatric Pulmonary Hypertension. The European Paediatric Pulmonary Vascular Disease Network, Endorsed by ISHLT and DGPK. Heart 2016; 102: ii42-ii48
44. Abman SH et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015; 132 (21)
45. Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Легочная артериальная гипертензия, ассоциированная с врожденными пороками сердца у взрослых. Методическое пособие. М.: НЦССХ им. А.Н.Бакулева, 2016; с. 833-50
46. Горбачевский С.В., Шмальц А.А., Плотникова Л.Р. Легочная гипертензия у детей с врожденными пороками сердца. М., 2018
47. Hansmann G, Koestenberger M, Alastalo T-P et al. 2019 Updated Consensus Statement on the Diagnosis and Treatment of Pediatric Pulmonary Hypertension. The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplantation 2019. DOI: 10.1016/j.healun
48. Lim ZS, Vettukattill JJ, Salmon AP et al. Sildenafil therapy in complex pulmonary atresia with pulmonary arterial hypertension. Int J Cardiol 2008; 129 (3): 339-43. DOI: 10.1016/j.ijcard.2007.08.016
49. Hosein RB, Clarke AJ, McGuirk SP et al. Factors influencing early and late outcome following the Fontan procedure in the current era. The ‘Two Commandments’? Eur J Cardiothorac 2007; 31 (3): 344-53
50. Bowater SE, Weaver RA, Thorne SA, Clift PF. The safety and effects of bosentan in patients with a Fontan circulation. Congenital Heart Dis 2012; 7 (3): 243-9
51. Shang XK, Li YP, Liu M et al. Efficacy of Endothelin Receptor Antagonist Bosentan on the Long-Term Prognosis in Patients After Fontan Operation. Zhonghua Xin Xue Guan Bing Za Zhi 2013; 41 (12): 1025-8
52. Schuuring MJ, Vis JC, van Dijk AP et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail 2013; 15 (6): 690-8
53. Hebert A, Mikkelsen UR, Thilen U et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation 2014; 130 (23): 2021-30
54. Derk G, Houser L, Miner P et al. Efficacy of Endothelin Blockade in Adults with Fontan Physiology. Congenital Heart Dis 2015; 10 (1): E11-E16
55. Shang XK, Lu R, Zhang X et al. Efficacy of Bosentan in patients after Fontan procedures: a double-blind, randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci 2016; 36 (4): 534-40. DOI: 10.1007/s11596-016-1621-8
56. Giardini A, Balducci A, Specchia S et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29 (13): 1681-7. https://doi.org/10.1093/eurheartj/ehn215
57. Reinhardt Z, Uzun O, Bhole V et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010; 20 (5): 522-5. DOI: 10.1017/S1047951110000648
58. Ciliberti P, Giardini A. Impact of oral chronic administration of sildenafil in children and young adults after the Fontan operation. Future Cardiol 2011; 7 (5): 609-12. DOI: 10.2217/fca.11.52
59. Van De Bruaene A, La Gerche A, Claessen G et al. Sildenafil Improves Exercise Hemodynamics in Fontan Patients. Circulation: Cardiovascular Imaging 2014; 7 (2): 265-73. DOI: 10.1161/circimaging.113.001243
60. Mori H, Park IS, Yamagishi H et al. Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. Int J Cardiol 2016; 221: 122-7. https://doi.org/10.1016/j.ijcard.2016.06.322
61. Collins JLG, Law MA, Borasino S et al. Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation. Pediatr Cardiol 2017; 38 (8): 1703-8. DOI: 10.1007/s00246-017-1716-4
62. Agnoletti G, Gala S, Ferroni F et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thoracic Cardiovasc Surg 2017; 153 (6): 1468-75. DOI: 10.1016/j.jtcvs.2017.01.051
63. Cedars AM, Saef J, Peterson LR et al. Effect of Ambrisentan on Exercise Capacity in Adult Patients After the Fontan Procedure. Am J Cardiol 2016; 117 (9): 1524-32. DOI: 10.1016/j.amjcard.2016.02.024
64. Rhodes J, Ubeda-Tikkanen A, Clair M et al. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol 2013; 168 (3): 2435-40. DOI: 10.1016/j.ijcard.2013.03.014
65. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J 2014; 35 (11): 691-700. https://doi.org/10.1093/eurheartj/eht437
66. Yamamura K, Nagata H, Ikeda K et al. Efficacy of bosentan therapy for segmental pulmonary artery hypertension due to major aortopulmonary collateral arteries in children. Int J Cardiol 2016; 161 (1): e1-e3
67. Onat A, Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 2012; 18 (11): 1465-77. DOI: 10.2174/138161212799504740
68. Попкова Т.В. и др. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008
69. Hoeper MM, Apitz C, Grünig E et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S: 37-45. DOI: 10.1016/j.ijcard.2018.08.082
70. Рекомендации Ассоциации ревматологов России по лечению ССД. 2016
71. Рекомендации Европейской противоревматической лиги по лечению ССД
72. Chazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Ter Arkh 2019; 91 (1): 24-31. DOI: 10.26442/00403660.2019.01.000024
73. Hamaguchi Y, Sumida T, Kawaguchi Y et al. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. J Dermatol 2017; 44 (1): 13-7. DOI: 10.1111/1346-8138.13497
74. Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70 (1): 32-8. DOI: 10.1136/ard.2010.130658
Рецензия
Для цитирования:
Мартынюк Т.В., Шмальц А.А., Клименко А.А. ЛАГ: за рамками идиопатической формы патологии. Системные гипертензии. 2020;17(2):84-90. https://doi.org/10.26442/2075082X.2020.2.200235
For citation:
Martynyuk T.A., Shmalts A.A., Klimenko A.A. PAH: beyond the idiopathic form of disease. Systemic Hypertension. 2020;17(2):84-90. (In Russ.) https://doi.org/10.26442/2075082X.2020.2.200235
Просмотров:
131
Послать статью по эл. почте 